The Female Condom as HIV Prevention
The Female Condom
In 2013, global investment related to female condom R&D totaled US$2.2 million (an increase of US$200,000 over 2012), from the Female Health Company and the Universal Access to Female Condoms (UAFC) Joint Programme, funded by the Netherlands Ministry of Foreign Affairs.
Between 2000 and 2013, approximately US$128 million was spent procuring 190 million female condoms through donor funding.18 Two female condoms are currently prequalified by the WHO, the FC2 and Cupid1. Two other designs, the Cupid2 and the Hindustan Lifecare Ltd. (HLL), were in a functionality study in 2013 with UAFC support, looking at safety, acceptability and performance. The results of the study will inform a product dossier submitted for WHO prequalification.
Other products were also submitted for WHO prequalification in 2013. The Shanghai Dahua Medical Apparatus Company in China tested its O’lavie female condom in a study in 2013, and the product is under review for WHO prequalification.